Yu Wang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Metastatic Colorectal Cancer

Mesenchymal Stem Cells

Top Venues

Cancer reports (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Shuwen Yang, Zhirong Sun, Changming Zhou, Wenjun Wei, Ning Qu, Rongliang Shi, Ben Ma, Weibo Xu, Qinhai Ji, Jun Zhang, Yu Wang
Feasibility of the enhanced neuromuscular blockade recovery protocol with selective use of sugammadex in thyroid surgery with intraoperative neuromonitoring. Head & neck (2024)
Shuwen Yang, Dongmei Ji, Fen Xue, Tongzhen Chen, Yu Wang, Qinhai Ji
Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma. Cancer reports (Hoboken, N.J.) 6 (1) (2022)
Shuwen Yang, Dongmei Ji, Fen Xue, Tongzhen Chen, Yu Wang, Qinhai Ji
Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma. Cancer reports (Hoboken, N.J.) 6 (1) (2022)
Shuwen Yang, Dongmei Ji, Fen Xue, Tongzhen Chen, Yu Wang, Qinhai Ji
Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma. Cancer reports (Hoboken, N.J.) 6 (1) (2022)
Shuwen Yang, Dongmei Ji, Fen Xue, Tongzhen Chen, Yu Wang, Qinhai Ji
Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma. Cancer reports (Hoboken, N.J.) (2022)